New drug combo tested for Tough-to-Treat ovarian cancer
NCT ID NCT05198804
Summary
This study tested a new drug called ZN-c3, both by itself and combined with an existing drug (niraparib), for women with advanced ovarian cancer that had stopped responding to platinum chemotherapy. The main goals were to find safe doses and see if the treatments could shrink tumors. It involved 117 women whose cancer had progressed despite prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona Oncology Associates (Wilmot HOPE) - USOR
Tucson, Arizona, 85711, United States
-
Centre Georges François Leclerc
Dijon, France
-
Centre Hospitalier Lyon Sud
Saint-Genis-Laval, France
-
Centre Oscar Lambret
Lille, France
-
EDOG - Institut Claudius Regaud
Toulouse, France
-
ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, France
-
Institut Gustave Roussy
Villejuif, France
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
MD Anderson Cancer Center, Gynecologic Oncology Center
Texas City, Texas, 77030, United States
-
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
Optimum Clinical Research Group- Women's Oncology
Albuquerque, New Mexico, 87109, United States
-
Rocky Mountain Cancer Centers
Aurora, Colorado, 80012, United States
-
Rutgers New Jersey Medical School
Newark, New Jersey, 07103, United States
-
Spectrum Health System
Grand Rapids, Michigan, 49503, United States
-
Texas Oncology-Fort Worth Cancer Center
Fort Worth, Texas, 76104, United States
-
The Blavatnik Family - Chelsea Medical Center at Mount Sinai
New York, New York, 10011, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
-
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, 97401, United States
-
Women and Infants Hospital of Rhode Island
Providence, Rhode Island, 02905, United States
Conditions
Explore the condition pages connected to this study.